- Home
- PFD vs BDTX Comparison
PFD vs BDTX Comparison
Compare PFD & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFD | BDTX |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 148.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PFD | BDTX |
|---|---|---|
| Price | $11.84 | $2.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | 33.2K | ★ 964.6K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 6.30% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | N/A | ★ $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.53 | $1.20 |
| 52 Week High | $11.18 | $4.94 |
Technical Indicators
Market Signals| Indicator | PFD | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 45.30 |
| Support Level | $11.70 | $2.49 |
| Resistance Level | $11.92 | $2.70 |
| Average True Range (ATR) | 0.13 | 0.15 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 48.00 | 46.15 |
Price Performance
Historical ComparisonAbout PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.